SeqLL Inc. Warrant (SQLLW)

Overview

SeqLL Inc. is a globally operating life sciences instrumentation and research services company focused on the development of scientific assets and novel intellectual property across various omics fields. At the core of SeqLL's offerings is its pioneering True Single Molecule Sequencing (tSMS) technology platform, specifically designed for DNA and RNA sequencing at the single molecule level. This technology aids researchers in accurately and reproducibly analyzing billions of single molecules in a single experiment. SeqLL Inc. not only caters to biomarker discovery and the development of diagnostic assays but also serves a broad spectrum of clients, including universities, scientific research centers, government institutions, and entities within the biotechnology and pharmaceutical industries. Founded in 2013, the company is headquartered in Billerica, Massachusetts, and has entered into various significant research and development agreements, including with the U.S. Department of Justice's Federal Bureau of Investigation, True Bearing Diagnostics, Inc., The Bernstein Laboratory, The Ting Laboratory, The Jackson Laboratory for Genomic Medicine, Weizmann Institute of Science, and Tetracore, Inc., showcasing its commitment to advancing scientific research and innovation.

Products and Services

• True Single Molecule Sequencing (tSMS) Technology Platform
  

  SeqLL Inc.'s flagship product, the True Single Molecule Sequencing platform, revolutionizes DNA and RNA sequencing by enabling researchers to detect nucleic acids at the single molecule level. This enables the analysis of billions of single molecules in a single experiment, providing highly accurate and reproducible data essential for various applications, including biomarker discovery and the development of diagnostic assays.

• Research and Development Agreement with the FBI
  

  SeqLL has entered into a research and development agreement with the U.S. Department of Justice's Federal Bureau of Investigation to evaluate and determine the forensic capabilities of direct RNA sequencing using its tSMS platform.

• Collaboration with True Bearing Diagnostics, Inc.
  

  The collaboration involves performing tSMS on whole-blood RNA to identify transcripts associated with coronary artery disease, showcasing SeqLL's commitment to advancing medical diagnostics.

• Scientific Collaborations for Chromatin Biology and Epigenetic Regulation
  

  SeqLL Inc. collaborates with The Bernstein Laboratory and The Ting Laboratory, among others, to address fundamental questions in chromatin biology and epigenetic regulation using its tSMS technology. These collaborations highlight the company's involvement in groundbreaking scientific research.

• Partnership with The Jackson Laboratory for Genomic Medicine
  

  This partnership assists in the development of new methods for chromatin interaction analysis in single nuclei with single-molecule resolution, emphasizing SeqLL's pivotal role in advancing genomic medicine.

• Weizmann Institute of Science Collaboration
  

  In collaboration with the Weizmann Institute of Science, SeqLL has developed and applied innovative single-molecule technologies, further solidifying its position as a leader in the field.

• Agreement with Tetracore, Inc.
  

  SeqLL provides tSMS systems and onsite support to Tetracore, Inc., demonstrating the company's flexible and supportive approach to its partnerships and its dedication to facilitating advancements in scientific research.